Symbols / SLNO
SLNO Chart
About
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.10B |
| Enterprise Value | 1.66B | Income | -78.45M | Sales | 98.67M |
| Book/sh | 9.21 | Cash/sh | 9.29 | Dividend Yield | — |
| Payout | 0.00% | Employees | 152 | IPO | — |
| P/E | — | Forward P/E | -17.25 | PEG | — |
| P/S | 21.32 | P/B | 4.25 | P/C | — |
| EV/EBITDA | -20.14 | EV/Sales | 16.79 | Quick Ratio | 15.77 |
| Current Ratio | 16.08 | Debt/Eq | 10.64 | LT Debt/Eq | — |
| EPS (ttm) | -1.75 | EPS next Y | -2.27 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-25 | ROA | -11.75% |
| ROE | -20.66% | ROIC | — | Gross Margin | 98.14% |
| Oper. Margin | 34.41% | Profit Margin | -79.50% | Shs Outstand | 53.71M |
| Shs Float | 49.91M | Short Float | 22.15% | Short Ratio | 6.06 |
| Short Interest | — | 52W High | 90.32 | 52W Low | 36.67 |
| Beta | -3.18 | Avg Volume | 1.51M | Volume | 885.27K |
| Target Price | $111.92 | Recom | Strong_buy | Prev Close | $39.65 |
| Price | $39.16 | Change | -1.24% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$111.92
Mean price target
2. Current target
$39.16
Latest analyst target
3. DCF / Fair value
$-1.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$39.16
Low
$60.00
High
$145.00
Mean
$111.92
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-20 | main | Wells Fargo | Overweight → Overweight | $114 |
| 2026-01-20 | main | HC Wainwright & Co. | Buy → Buy | $120 |
| 2025-11-18 | init | Wolfe Research | — → Outperform | $75 |
| 2025-11-05 | main | Wells Fargo | Overweight → Overweight | $106 |
| 2025-08-27 | reit | Guggenheim | Buy → Buy | $106 |
| 2025-08-20 | init | Wells Fargo | — → Overweight | $123 |
| 2025-08-18 | main | HC Wainwright & Co. | Buy → Buy | $110 |
| 2025-08-07 | main | Guggenheim | Buy → Buy | $106 |
| 2025-08-07 | main | Oppenheimer | Outperform → Outperform | $110 |
| 2025-07-11 | main | Baird | Outperform → Outperform | $121 |
| 2025-05-08 | main | Guggenheim | Buy → Buy | $97 |
| 2025-05-08 | main | Baird | Outperform → Outperform | $105 |
| 2025-04-24 | main | Piper Sandler | Overweight → Overweight | $145 |
| 2025-04-15 | reit | HC Wainwright & Co. | Buy → Buy | $100 |
| 2025-03-31 | main | HC Wainwright & Co. | Buy → Buy | $100 |
| 2025-03-28 | main | Stifel | Buy → Buy | $108 |
| 2025-03-28 | main | Guggenheim | Buy → Buy | $81 |
| 2025-03-27 | main | Laidlaw & Co. | Buy → Buy | $105 |
| 2025-03-27 | main | Baird | Outperform → Outperform | $102 |
| 2025-03-27 | main | Cantor Fitzgerald | Overweight → Overweight | $123 |
- Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Biotech Contender with 184% Upside Potential - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- Solena Therapeutics (SLNO) Stock Under Pressure But Upside is Huge - Yahoo Finance ue, 27 Jan 2026 08
- What to Expect from Soleno Therapeutics's Earnings - Benzinga ue, 24 Feb 2026 18
- New Prader-Willi treatment from Soleno tops 1,200 patient starts in months - Stock Titan Mon, 12 Jan 2026 08
- Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman - PR Newswire Fri, 07 Nov 2025 08
- $SLNO stock is down 13% today. Here's what we see in our data. - Quiver Quantitative Wed, 01 Oct 2025 07
- Soleno Stock: Blockbuster Launch In Progress (NASDAQ:SLNO) - Seeking Alpha Sat, 11 Oct 2025 07
- Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Eastern Progress Sat, 07 Feb 2026 14
- Is Soleno Therapeutics Stock Built to Withstand More Downside? - Trefis Sun, 21 Dec 2025 08
- Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround - Yahoo Finance Mon, 02 Feb 2026 08
- Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Promising 77% Upside in the Biotech Sector - DirectorsTalk Interviews Mon, 03 Nov 2025 08
- Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance - Yahoo Finance Mon, 16 Feb 2026 17
- Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance hu, 11 Sep 2025 07
- Soleno Therapeutics (SLNO) Jumps 13.46% as Competitor Fails Prader-Willi Treatment Trial - Yahoo Finance hu, 25 Sep 2025 07
- Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating - Yahoo Finance Fri, 17 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 28600 | — | — | Stock Award(Grant) at price 0.00 per share. | MACKANESS JAMES H | Chief Financial Officer | — | 2026-01-21 00:00:00 | D |
| 1 | 114200 | — | — | Stock Award(Grant) at price 0.00 per share. | ANISH BHATNAGAR | Chief Executive Officer | — | 2026-01-21 00:00:00 | D |
| 2 | 10400 | — | — | Stock Award(Grant) at price 0.00 per share. | YEN KRISTEN | Officer | — | 2026-01-21 00:00:00 | D |
| 3 | 28600 | — | — | Stock Award(Grant) at price 0.00 per share. | MANNING MEREDITH S. | Officer | — | 2026-01-21 00:00:00 | D |
| 4 | 10400 | — | — | Stock Award(Grant) at price 0.00 per share. | HIRANO PATRICIA C | Officer | — | 2026-01-21 00:00:00 | D |
| 5 | 3500 | — | — | Stock Award(Grant) at price 0.00 per share. | NORRETT KEVIN | Officer | — | 2026-01-21 00:00:00 | D |
| 6 | 4100 | — | — | Stock Award(Grant) at price 0.00 per share. | JOSHI MANHER | Officer | — | 2026-01-21 00:00:00 | D |
| 7 | 10400 | — | — | Stock Award(Grant) at price 0.00 per share. | HUANG MICHAEL F | Officer | — | 2026-01-21 00:00:00 | D |
| 8 | 100000 | — | — | Stock Gift at price 0.00 per share. | ANISH BHATNAGAR | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 9 | 14286 | — | — | Stock Award(Grant) at price 0.00 per share. | NORRETT KEVIN | Officer | — | 2025-11-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -170.39M | -34.13M | -22.84M | -31.54M |
| TotalUnusualItems | -3.24M | -2.90M | 742.00K | 1.24M |
| TotalUnusualItemsExcludingGoodwill | -3.24M | -2.90M | 742.00K | 1.24M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -175.85M | -38.99M | -24.07M | -30.91M |
| ReconciledDepreciation | 1.99M | 1.96M | 1.96M | 1.96M |
| EBITDA | -173.63M | -37.03M | -22.10M | -30.30M |
| EBIT | -175.62M | -38.99M | -24.07M | -32.26M |
| NetInterestIncome | 11.82M | 2.58M | 300.00K | 110.00K |
| InterestExpense | 231.00K | 0.00 | 0.00 | |
| InterestIncome | 12.05M | 2.58M | 300.00K | 110.00K |
| NormalizedIncome | -172.61M | -36.09M | -24.81M | -32.15M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -175.85M | -38.99M | -24.07M | -30.91M |
| TotalExpenses | 184.43M | 38.67M | 25.11M | 32.26M |
| TotalOperatingIncomeAsReported | -187.67M | -41.38M | -24.40M | -31.53M |
| DilutedAverageShares | 40.18M | 16.49M | 8.40M | 5.32M |
| BasicAverageShares | 40.18M | 16.49M | 8.40M | 5.32M |
| DilutedEPS | -4.38 | -2.36 | -2.87 | -5.81 |
| BasicEPS | -4.38 | -2.36 | -2.87 | -5.81 |
| DilutedNIAvailtoComStockholders | -175.85M | -38.99M | -24.07M | -30.91M |
| NetIncomeCommonStockholders | -175.85M | -38.99M | -24.07M | -30.91M |
| NetIncome | -175.85M | -38.99M | -24.07M | -30.91M |
| NetIncomeIncludingNoncontrollingInterests | -175.85M | -38.99M | -24.07M | -30.91M |
| NetIncomeContinuousOperations | -175.85M | -38.99M | -24.07M | -30.91M |
| PretaxIncome | -175.85M | -38.99M | -24.07M | -30.91M |
| OtherIncomeExpense | -3.24M | -2.90M | 742.00K | 1.24M |
| SpecialIncomeCharges | -3.24M | -2.71M | 712.00K | 731.00K |
| RestructuringAndMergernAcquisition | 3.24M | 2.71M | -712.00K | -731.00K |
| GainOnSaleOfSecurity | -182.00K | 30.00K | 508.00K | |
| NetNonOperatingInterestIncomeExpense | 11.82M | 2.58M | 300.00K | 110.00K |
| InterestExpenseNonOperating | 231.00K | 0.00 | 0.00 | |
| InterestIncomeNonOperating | 12.05M | 2.58M | 300.00K | 110.00K |
| OperatingIncome | -184.43M | -38.67M | -25.11M | -32.26M |
| OperatingExpense | 184.43M | 38.67M | 25.11M | 32.26M |
| ResearchAndDevelopment | 78.57M | 25.19M | 15.27M | 21.45M |
| SellingGeneralAndAdministration | 105.86M | 13.48M | 9.84M | 10.81M |
| GeneralAndAdministrativeExpense | 105.86M | 13.48M | 9.84M | 10.81M |
| OtherGandA | 105.86M | 13.48M | 9.84M | 10.81M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 45.70M | 31.68M | 8.16M | 5.32M |
| ShareIssued | 45.70M | 31.68M | 8.16M | 5.32M |
| TotalDebt | 52.83M | 403.00K | 155.00K | 457.00K |
| TangibleBookValue | 238.31M | 148.76M | -345.00K | 5.16M |
| InvestedCapital | 294.94M | 157.51M | 10.35M | 17.79M |
| WorkingCapital | 275.14M | 159.85M | 8.33M | 14.41M |
| NetTangibleAssets | 238.31M | 148.76M | -345.00K | 5.16M |
| CapitalLeaseObligations | 3.00M | 403.00K | 155.00K | 457.00K |
| CommonStockEquity | 245.11M | 157.51M | 10.35M | 17.79M |
| TotalCapitalization | 294.94M | 157.51M | 10.35M | 17.79M |
| TotalEquityGrossMinorityInterest | 245.11M | 157.51M | 10.35M | 17.79M |
| StockholdersEquity | 245.11M | 157.51M | 10.35M | 17.79M |
| GainsLossesNotAffectingRetainedEarnings | 361.00K | 0.00 | ||
| OtherEquityAdjustments | 361.00K | |||
| RetainedEarnings | -452.26M | -276.41M | -237.42M | -213.35M |
| AdditionalPaidInCapital | 696.97M | 433.88M | 247.76M | 231.07M |
| CapitalStock | 46.00K | 32.00K | 8.00K | 80.00K |
| CommonStock | 46.00K | 32.00K | 8.00K | 80.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 85.86M | 23.18M | 16.15M | 17.76M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 67.11M | 11.68M | 8.84M | 9.75M |
| OtherNonCurrentLiabilities | 14.81M | 11.55M | 8.84M | 9.55M |
| DerivativeProductLiabilities | 0.00 | 1.00K | 31.00K | |
| LongTermDebtAndCapitalLeaseObligation | 52.30M | 130.00K | 0.00 | 175.00K |
| LongTermCapitalLeaseObligation | 2.47M | 130.00K | 0.00 | 175.00K |
| LongTermDebt | 49.83M | |||
| CurrentLiabilities | 18.75M | 11.51M | 7.31M | 8.01M |
| OtherCurrentLiabilities | 2.74M | 1.55M | 484.00K | 323.00K |
| CurrentDebtAndCapitalLeaseObligation | 526.00K | 273.00K | 155.00K | 282.00K |
| CurrentCapitalLeaseObligation | 526.00K | 273.00K | 155.00K | 282.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.78M | 3.13M | 1.68M | 728.00K |
| PayablesAndAccruedExpenses | 10.71M | 6.54M | 5.00M | 6.67M |
| CurrentAccruedExpenses | 1.83M | 3.39M | 3.22M | 3.42M |
| Payables | 8.88M | 3.15M | 1.78M | 3.25M |
| AccountsPayable | 8.88M | 3.15M | 1.78M | 3.25M |
| TotalAssets | 330.97M | 180.69M | 26.50M | 35.55M |
| TotalNonCurrentAssets | 37.08M | 9.33M | 10.85M | 13.13M |
| OtherNonCurrentAssets | 83.00K | 165.00K | 40.00K | |
| InvestmentsAndAdvances | 27.21M | 0.00 | ||
| InvestmentinFinancialAssets | 27.21M | 0.00 | ||
| AvailableForSaleSecurities | 27.21M | |||
| GoodwillAndOtherIntangibleAssets | 6.80M | 8.75M | 10.69M | 12.64M |
| OtherIntangibleAssets | 6.80M | 8.75M | 10.69M | 12.64M |
| NetPPE | 2.98M | 419.00K | 157.00K | 454.00K |
| AccumulatedDepreciation | -70.00K | -89.00K | -75.00K | -68.00K |
| GrossPPE | 3.05M | 508.00K | 232.00K | 522.00K |
| Leases | 52.00K | 0.00 | ||
| OtherProperties | 2.80M | 407.00K | 131.00K | 421.00K |
| MachineryFurnitureEquipment | 204.00K | 101.00K | 101.00K | 101.00K |
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 293.89M | 171.36M | 15.65M | 22.42M |
| OtherCurrentAssets | 2.45M | 1.68M | 1.04M | 1.12M |
| PrepaidAssets | 1.12M | |||
| CashCashEquivalentsAndShortTermInvestments | 291.44M | 169.68M | 14.60M | 21.30M |
| OtherShortTermInvestments | 203.51M | 0.00 | ||
| CashAndCashEquivalents | 87.93M | 169.68M | 14.60M | 21.30M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -69.31M | -24.94M | -20.79M | -27.79M |
| RepaymentOfDebt | 0.00 | -8.00K | ||
| IssuanceOfDebt | 49.89M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 148.96M | 137.86M | 14.11M | 0.00 |
| CapitalExpenditure | -218.00K | -13.00K | -22.00K | |
| EndCashPosition | 87.93M | 169.68M | 14.60M | 21.30M |
| BeginningCashPosition | 169.68M | 14.60M | 21.30M | 49.22M |
| ChangesInCash | -81.75M | 155.08M | -6.70M | -27.92M |
| FinancingCashFlow | 213.03M | 180.02M | 14.09M | -128.00K |
| CashFlowFromContinuingFinancingActivities | 213.03M | 180.02M | 14.09M | -128.00K |
| NetOtherFinancingCharges | -16.00K | -120.00K | ||
| ProceedsFromStockOptionExercised | 14.18M | 42.16M | 0.00 | 0.00 |
| NetCommonStockIssuance | 148.96M | 137.86M | 14.11M | 0.00 |
| CommonStockIssuance | 148.96M | 137.86M | 14.11M | 0.00 |
| NetIssuancePaymentsOfDebt | 49.89M | 0.00 | 0.00 | -8.00K |
| NetLongTermDebtIssuance | 49.89M | 0.00 | 0.00 | -8.00K |
| LongTermDebtPayments | 0.00 | -8.00K | ||
| LongTermDebtIssuance | 49.89M | 0.00 | 0.00 | |
| InvestingCashFlow | -225.68M | 0.00 | -13.00K | -22.00K |
| CashFlowFromContinuingInvestingActivities | -225.68M | 0.00 | -13.00K | -22.00K |
| NetInvestmentPurchaseAndSale | -225.46M | 0.00 | 0.00 | |
| SaleOfInvestment | 131.00M | 0.00 | 0.00 | |
| PurchaseOfInvestment | -356.46M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -218.00K | 0.00 | -13.00K | -22.00K |
| PurchaseOfPPE | -218.00K | 0.00 | -13.00K | -22.00K |
| OperatingCashFlow | -69.10M | -24.94M | -20.78M | -27.77M |
| CashFlowFromContinuingOperatingActivities | -69.10M | -24.94M | -20.78M | -27.77M |
| ChangeInWorkingCapital | 6.02M | 2.93M | -756.00K | -1.15M |
| ChangeInOtherWorkingCapital | 1.46M | 947.00K | -277.00K | |
| ChangeInOtherCurrentLiabilities | 1.02M | 762.00K | -141.00K | -128.00K |
| ChangeInPayablesAndAccruedExpense | 5.75M | 3.00M | -728.00K | -604.00K |
| ChangeInAccruedExpense | 74.00K | 1.63M | 749.00K | -369.00K |
| ChangeInPayable | 5.67M | 1.37M | -1.48M | -235.00K |
| ChangeInAccountPayable | 5.67M | 1.37M | -1.48M | -235.00K |
| ChangeInPrepaidAssets | -750.00K | -837.00K | 113.00K | -139.00K |
| OtherNonCashItems | 3.69M | 3.04M | -422.00K | -443.00K |
| StockBasedCompensation | 99.96M | 5.95M | 2.53M | 3.28M |
| AmortizationOfSecurities | -4.89M | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 1.99M | 1.96M | 1.96M | 1.96M |
| DepreciationAndAmortization | 1.99M | 1.96M | 1.96M | 1.96M |
| OperatingGainsLosses | 182.00K | -30.00K | -508.00K | |
| GainLossOnInvestmentSecurities | 182.00K | -30.00K | -508.00K | |
| NetIncomeFromContinuingOperations | -175.85M | -38.99M | -24.07M | -30.91M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SLNO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|